By Carl Zimmer and Azeen Ghorayshi Scientists have uncovered a wealth of clues about how genetic mutations lead to severe forms of autism, offering opportunities for testing drugs that could treat the condition, according to a study published Thursday. The researchers charted how mutations change the way proteins work together in cells, altering the development of the brain. “This is making maps of unknown territories that’s really necessary to move the biology forward,” said Dan Geschwind, a neurogeneticist at the University of California, Los Angeles, who was not involved in the study. Researchers have been studying autism for over 80 years, but it has only been in recent years that they have been able to explore its molecular biology. One reason that progress has been so slow is that autism is not just one condition, but a broad constellation of them. People with autism can have difficulty with language and making social connections, and often display restricted or repetitive behaviors. While many children with an autism diagnosis can grow up to lead independent adult lives, others may be nonspeaking, have intellectual disabilities, and require round-the-clock care. But in around 30 percent of people diagnosed with autism, typically those with the most severe disabilities, scientists have identified single gene mutations that are almost guaranteed to cause the disorder. When those genes started coming to light 20 years ago, scientists eagerly hoped they could find precise treatments for severe autism. In some studies, they engineered mice with the mutations and then tried different drugs to reverse their autism-like symptoms. But those efforts have not led to any effective treatment targeting a specific gene. © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30390 - Posted: 08.29.2026

By Claudia López Lloreda The proteins encoded by 100 genes involved in autism form an interconnected network consisting of multiple protein complexes that serve different cellular functions, according to a study published today in Science. Autism-associated variants may cause this network to rewire, the study also found. Even though autism is a genetically heterogeneous condition, “when you look at the proteins encoded by the genes, and also the specific mutations and the interfaces of protein interactions, the biology starts to converge,” says Kasper Lage, managing director of the Novo Nordisk Foundation Center at the Broad Institute, who was not involved in the work. Many of the proteins the study considered converge on complexes already associated with autism and that are involved in processes such as neural progenitor proliferation and differentiation and neuronal migration, the researchers found. The idea behind the work was to go beyond the genetic studies, which have linked about 250 genes to autism, says study investigator Belinda Wang, assistant professor of psychiatry at the University of California, San Francisco. “Genes can tell us where autism risk begins, but proteins do a lot of the work inside the cells, and so by studying autism at the protein level, maybe this can give us a more direct view of the underlying biology.” Previous network analyses did not reach this magnitude, Lage says. “When you get to the scale that they’re doing in this paper, you can start to do really interesting secondary analysis and pathway and discovery.” © 2026 Simons Foundation

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30388 - Posted: 08.29.2026

By Aimee Cunningham In 2025, the number of children receiving a drug promoted — but unproven — for autism treatment grew, especially toward the end of the year. A new study suggests the late rise was influenced by a Trump administration announcement. At a White House briefing on September 22, 2025, President Trump touted the drug leucovorin as a potential therapeutic for autism. The week before the announcement, roughly 5 children per 100,000 received leucovorin via a prescription in the United States. The week of the announcement, the pharmacy dispensing rate climbed to roughly 7 children per 100,000. By the end of the year, the rate rose to 8 children per 100,000, researchers reported August 12 in the New England Journal of Medicine. “Our study demonstrates the power of the federal government to influence clinical practice,” says Kao-Ping Chua, a pediatrician and health policy researcher at the University of Michigan Medical School in Ann Arbor. If administration communications and decisions are not based on rigorous scientific evidence, it could lead to harms “including giving people false hope and potentially exposing them to the side effects of ineffective medical treatments.” Leucovorin is a form of the essential vitamin folic acid. The drug is prescribed when the body’s method for breaking down folic acid from food is impaired. The U.S. Food and Drug Administration had approved leucovorin for use with certain genetic disorders and to help reduce the side effects of chemotherapy drugs that disrupt that break down. The American Academy of Pediatrics does not recommend leucovorin for autism because of the lack of evidence surrounding dosing, effectiveness and safety. © Society for Science & the Public 2000–2026.

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30380 - Posted: 08.22.2026

By Azeen Ghorayshi In early June, Ally Betchan and her family made the monthly trek from their small central Texas town to a therapy center in Austin, hoping that she could learn to communicate. Like nearly 30 percent of people with autism, Ally is severely disabled and does not speak. Ally, 22, sat quietly in a small room next to her instructor, Soma Mukhopadhyay, a sprightly 63-year-old who, by contrast, talked almost nonstop. More than 30 years ago, Ms. Mukhopadhyay taught her nonspeaking autistic son, Tito, to write and type independently, creating a communication method that supporters hailed as transformative and critics have challenged ever since. Ms. Mukhopadhyay held up a clear plastic sheet marked with the alphabet, prompting Ally to make up a story. As Ally tugged rhythmically at her purse, she slowly pointed at letters to spell “DONNA KNOWS,” and then seemed to get stuck, pointing to a jumble of letters. “I’m so lost,” Ms. Mukhopadhyay said, shaking the sheet and pressing her to try again. As Ms. Mukhopadhyay occasionally tapped under the letter board on her thigh or leaned in the direction of a letter, Ally eventually spelled: “CARING HURTS.” “‘Donna knows caring hurts’ — that is a life lesson,” Ms. Mukhopadhyay said, nodding in agreement. Then, Ally jabbed many letters in quick succession, but distinctly: “SHE LOVES THOSE WHO CARE FOR HER.” Sitting beside her, Ally’s mother, aunt and grandmother smiled. Ms. Mukhopadhyay’s technique, called the Rapid Prompting Method, or R.P.M., is one of several intended to help nonverbal people learn to communicate using letter boards held in midair by another person. At the core of these assisted spelling methods is a radical assertion: that nonspeaking autistic people, many of whom have been considered intellectually disabled their whole lives, may have typical or even extraordinary cognitive abilities, obscured by motor problems and an overwhelmed sensory system that has cut them off from the world around them. © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior; Chapter 19: Language and Lateralization
Related chapters from MM:Chapter 13: Memory and Learning; Chapter 15: Language and Lateralization
Link ID: 30314 - Posted: 07.08.2026

Sarah Hendrickx Being autistic can be a lot of fun. I say that as an adult-diagnosed autistic (and ADHD) adult who has spent the past 20 years working in the autism world, meeting thousands of autistic people and their families, writing books, and speaking publicly on the subject. It’s not always fun, that’s for sure, but given that the nature of being human comes with a whole plethora of complexities and contradictions, light and dark, it is, of course, highly possible that a package of atypical cognitive processes, perceptions and behaviours clinically categorised as dysfunctional and disabling can also bring a whole load of satisfaction and pleasure. Even so, I imagine that, for some people, the concept of being autistic as being joyful is a tough one to square, given that the diagnostic criteria for autism spectrum disorder defines it as ‘characterised by varying but often marked and persistent deficits in social communication and social interaction’. Still not convinced? Let’s think of being autistic in the same way that we think of a socially driven person who may thrive and excel in a busy environment, and then struggle when alone, or of a highly moral person who may be jubilant when justice prevails, and then devastated when it does not – in other words, one natural tendency can bring us both challenges and elation, depending on the circumstances. The same is true for autistic characteristics. I should note that the following celebration of autistic delight does not negate or trivialise the very real and often disabling experience of living as an autistic person in a non-autistic world. I also recognise my own privilege as an autistic adult who is able to live relatively independently and with agency, but also as an autistic adult who – despite appearances – received my own diagnosis of autism by fair means, complete with the requisite impairments and deficits. © Aeon Media Group Ltd. 2012-2026.

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior; Chapter 16: Psychopathology: Biological Basis of Behavior Disorders
Related chapters from MM:Chapter 13: Memory and Learning; Chapter 12: Psychopathology: The Biology of Behavioral Disorders
Link ID: 30274 - Posted: 06.10.2026

By Sarah Kliff and Margot Sanger-Katz On a sunny Wednesday morning last month, dozens of preschoolers filed into a Compleat Kidz autism clinic in Concord, N.C. One wore light-up sneakers. Another had a Spider-Man lunchbox. They settled into tiny green cubicles, each accompanied by a staff member, and started their work. A decade ago, this Charlotte suburb had no clinics providing therapy to children with autism. Now it has 12. Inside this one, children buzzed with activity as they worked long sessions with therapists. One 6-year-old girl, exhausted after hours of therapy, fell fast asleep in her therapist’s lap. Soon, a supervisor, Stephen Schroeder, intervened. “How long?” Mr. Schroeder asked Courtney Evans, the therapist. “I set the timer for 7. We’re almost done,” Ms. Evans said. A couple of minutes later, she nudged the child awake. The girl cried. At Compleat Kidz, a fast-growing chain of autism clinics based in North Carolina, the policy is firm: Naps cannot be longer than seven minutes before children are awakened to resume therapy. The company says this is necessary to prevent fraud since clinics can be paid only when children are awake and getting services. But it also allows the clinic to bill insurers or Medicaid for more hours. Across the United States, where treatment for autistic children was once fairly rare, thousands of clinics have sprung up, turning a once obscure therapy into a multibillion-dollar industry. The growth has been fueled by rising autism diagnoses, state insurance mandates and a federal requirement that Medicaid cover the therapy. Private equity investors have rushed into the business, buying up chains and opening new clinics.. © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30254 - Posted: 05.23.2026

By Azeen Ghorayshi Health Secretary Robert F. Kennedy Jr. has overhauled a panel that helps the federal government set priorities for autism research and social services, installing several members who have said that vaccines can cause autism despite decades of research that has failed to establish such a link. The panel, the Interagency Autism Coordinating Committee, was established in 2000 and has historically included autistic people, parents, scientists and clinicians, as well as federal employees, who hold public meetings to debate how federal funds should best be allocated to support people with autism. The 21 new public members selected by Mr. Kennedy include many outspoken activists, among them a former employee of a super PAC that supported Mr. Kennedy’s presidential campaign, a doctor who has been sued over dangerous heavy metal treatments for a young child with autism, a political economist who has testified against vaccines before a congressional committee, and parents who have spoken publicly about their belief that their children’s autism was caused by vaccines. The group, which also includes 21 government members across many federal agencies, will advise the federal government on how to prioritize the $2 billion allocated by Congress toward autism research and services over the next five years. Though it’s not yet clear what the committee will do — or what it can do, given that it serves only an advisory function — many longtime autism advocates and researchers said they were alarmed by the fact that the committee seemed stacked to advance Mr. Kennedy’s priorities on vaccines. “The new committee does not represent the autism community,” said Alison Singer, who served on the committee from 2007 to 2019. Ms. Singer, whose 28-year-old daughter has profound autism, is the head of the Autism Science Foundation. “It disproportionately, excruciatingly so, represents an extremely small subset of families who believe vaccines cause autism.” © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30100 - Posted: 01.31.2026

Jon Hamilton At a press conference in late 2025, federal officials made some big claims about leucovorin, a prescription drug usually reserved for people on cancer chemotherapy. "We're going to change the label to make it available [to children with autism spectrum disorder]," said Dr. Marty Makary, commissioner of the Food and Drug Administration. "Hundreds of thousands of kids, in my opinion, will benefit." The Trump administration has suggested that leucovorin, a drug used in cancer treatment, might have some benefit for children with autism. Many researchers and families aren't so sure. The FDA still hasn't made that label change. Since Makary's remarks, though, more than 25,000 people have joined a Facebook group called Leucovorin for Autism. Most members appear to be parents seeking the drug for their autistic children. Also since the press conference, some doctors have begun writing off-label prescriptions for autistic children, against the advice of medical groups including the American Academy of Pediatrics. The buzz about leucovorin has led to a shortage of the drug. In response, the FDA is temporarily allowing imports of tablets that are made in Spain and sold in Canada, but not approved in the U.S. All of this is part of a familiar cycle for Dr. Paul Offit, who directs the vaccine education center at Children's Hospital of Philadelphia. Offit says he realized years ago that leucovorin's popularity was far ahead of the science. Jason Mazzola walks to work at The Residence at Natick South, an LCB Senior Living community in Natick, MA. August 22, 2024. © 2026 npr

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30095 - Posted: 01.28.2026

By Azeen Ghorayshi A scientific review of 43 studies on acetaminophen use during pregnancy concluded that there was no evidence that the painkiller increased the risk of autism or other neurodevelopmental disorders. “We found no clinically important increase in the risk of autism, A.D.H.D. or intellectual disability,” Dr. Asma Khalil, a professor of obstetrics and maternal fetal medicine at St. George’s Hospital, University of London, and the lead author of the report, said at a news briefing. The study was published on Friday in the British medical journal The Lancet. Acetaminophen, the active ingredient in Tylenol, remains “the first-line treatment that we would recommend if the pregnant women have pain or fever in pregnancy,” Dr. Khalil said. Studies that have examined a possible link between acetaminophen in pregnancy and a risk of neurodevelopmental disorders have produced conflicting data, with some finding no connection and others finding small increases in risk. The new review comes after President Trump told pregnant women during a news conference in September to “tough it out” and “fight like hell” not to take Tylenol, because he said the painkiller could cause autism in children. The message was delivered as part of a broader campaign by Health Secretary Robert F. Kennedy Jr. to try to identify the causes behind rising autism rates among children in the United States, zeroing in on the unproven risks of acetaminophen and long-discredited theories that vaccines cause autism. Medical groups worldwide, including the American College of Obstetricians and Gynecologists, quickly disputed the president’s statements. They argued that doctors already advised their pregnant patients to use acetaminophen judiciously, and cautioned that untreated fevers during pregnancy could cause health problems for the mother and the baby © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30085 - Posted: 01.17.2026

By Azeen Ghorayshi Academic research labs across the country are working to find biological markers that can predict whether a child is at risk of developing autism. And companies are rushing to turn the findings into commercial tests, despite limited evidence to back their validity, raising concerns that their results could mislead desperate parents. They include one test that examines a strand of hair to rule out an autism diagnosis in babies as young as one month old. Two other tests just entered the market. One promises to predict autism risk based on skin cells collected as early as days after birth. Another looks for the presence of certain antibodies in a mother’s blood to determine whether her children, or babies that she might have in the future, are at risk of developing autism. For decades, clinicians and parents have hoped for a biological test that could help determine if a child has autism. The push to commercialize investigators’ early research has accelerated as Health Secretary Robert F. Kennedy Jr. has elevated the neurodevelopmental disorder into a national political priority, creating new funding for autism research and reviving long-discredited theories about autism and vaccines. But the new tests, largely aimed as a screening tool for the general population, are not yet reliable enough to be offered commercially, outside scientists familiar with the tests say, especially in a landscape where families are already inundated with incorrect or unverified information about autism. None of the tests has gone through large experimental trials or had its validity evaluated by a regulatory agency. “All of these tests are interesting hypotheses,” said Joseph Buxbaum, a neuroscientist at the Icahn School of Medicine at Mount Sinai who studies the genetics of autism. But they are “absolutely not at a point for any kind of clinical use,” he said. © 2026 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 30076 - Posted: 01.10.2026

On 19 November 2025, the U.S. Centers for Disease Control and Prevention changed language on a “vaccine safety” page on its website to assert that the statement “vaccines do not cause autism” is not evidence based. The updated CDC page now incorrectly suggests that a link between infant vaccination and autism exists, and it casts doubt on a wealth of research that has produced evidence to the contrary. The updated language contradicts decades of research findings that show vaccines do not cause autism. The move has also prompted backlash from multiple groups, including the Coalition of Autism Scientists and the Autism Science Foundation. “These sort of claims have been repeatedly debunked by good science and multiple independent replications of negative studies, and for years no scientist has opined that more research is needed,” Eric Fombonne, professor emeritus of psychiatry at Oregon Health & Science University, told The Transmitter. He noted several problems with the arguments presented on the CDC website, including the citation of “fringe studies executed by uncredentialed authors with poor methodologies and published in low-quality journals.” Fombonne described the authors of the page as having “cherry pick[ed data] … in support of their preconceived beliefs” and mischaracterizing well-conducted and replicated research. Experts The Transmitter spoke with raised many concerns about the agency’s statements, including how those statements could confuse families and whether they indicate shifts in priorities that threaten solid scientific research. “Families deserve honest answers,” says David Mandell, professor of psychiatry at the University of Pennsylvania and director of the Penn Center for Mental Health. © 2025 Simons Foundation

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior; Chapter 15: Emotions, Aggression, and Stress
Related chapters from MM:Chapter 13: Memory and Learning; Chapter 11: Emotions, Aggression, and Stress
Link ID: 30020 - Posted: 11.22.2025

By Lauren Schenkman The purported autism-microbiome connection is having a moment. It’s the focus of a new $50-million call for proposals from Wellcome Leap—a research initiative of the Wellcome Trust—and a 2024 Netflix documentary portrays fecal microbiota transplants as a promising treatment for autism-related traits. “It seems to have captured the public’s imagination,” says Kevin Mitchell, associate professor of genetics and neuroscience at Trinity College in Dublin. But Mitchell says he has long been skeptical. Eventually, he and some colleagues “collectively got exasperated enough by this that we felt that we had to say something about it,” Mitchell says. Today, they published a comprehensive review in Neuron of more than 30 studies on the autism-microbiome connection, including preclinical experiments in mice, human observational studies and clinical trials. After accounting for statistical, technical and conceptual flaws, the team reached a clear conclusion: “There’s nothing there,” Mitchell says. Research projects that include the keywords “autism” and “microbiome” have netted about $20 million to $25 million in U.S. federal funding annually since 2018, Mitchell’s team found using the funding database NIH RePORTER. It’s worrying that funders assume “there’s a solid foundation of work,” Mitchell says. “It’s just this huge amount of scientific effort and funding going into exploring these ideas.” Mitchell spoke with The Transmitter about the problems he sees with studies that claim to show a microbiome-autism link, and how neuroscientists can read them with an analytical eye. © 2025 Simons Foundation

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior; Chapter 13: Homeostasis: Active Regulation of the Internal Environment
Related chapters from MM:Chapter 13: Memory and Learning; Chapter 9: Homeostasis: Active Regulation of the Internal Environment
Link ID: 30015 - Posted: 11.19.2025

By Giorgia Guglielmi Male and female human fetuses show distinct patterns of gene activity and DNA regulation in the cerebral cortex, according to a new analysis of thousands of individual brain cells. The study offers one of the most detailed maps to date of how such activity differs between boys and girls’ brains during the second trimester. It also compares sex differences in gene activity in fetuses with spontaneous genetic changes in autistic people, revealing clues as to how these de novo changes affect boys and girls. “As the field evolves, this [work] will be a helpful reference” for exploring sex-related molecular differences in early brain development, says Matthew Oetjens, assistant professor of human genetics at Geisinger Medical Center, who was not involved in the study. Understanding these differences may help explain why certain neurodevelopmental conditions are more common in one sex than the other, he says. Autism, for example, is diagnosed about four times more often in boys than in girls, but scientists are still trying to understand why. Theories include the possibility that boys are more vulnerable, girls are sometimes protected, or a combination of both. “We know that autism … has a very strong genetic component. What is not known is how the genetic risk architecture intersects with any differences at the molecular level that might exist between male and female human brains,” says study investigator Tomasz Nowakowski, associate professor of neurological surgery, anatomy and psychiatry, and behavioral sciences at the University of California, San Francisco. More than 940 genes are expressed differently between the sexes, according to the new analysis of more than 38,000 brain cells from 21 female and 27 male mid-gestation fetuses. Most of these differentially expressed genes are more active in females. © 2025 Simons Foundation

Related chapters from BN: Chapter 12: Sex: Evolutionary, Hormonal, and Neural Bases; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 8: Hormones and Sex; Chapter 13: Memory and Learning
Link ID: 29977 - Posted: 10.22.2025

By Azeen Ghorayshi As a child, Jodie Singer barely spoke. She could repeat words that people said to her or recite the book “Madeline” from beginning to end, but she could not answer yes or no when her mother asked if she wanted juice. Sometimes she hurt herself, compulsively tearing at the skin and hair on the nape of her neck. She threw tantrums, thrashing and refusing to be comforted. When she was almost 3, Jodie was given a diagnosis of autism. Now 28, she still speaks only in short, repetitive phrases and requires round-the-clock care, including help eating, getting dressed and using the toilet. At the time Jodie’s diagnosis was first made, the definition of autism was expanding, as it would continue to do over the next 25 years. Once primarily limited to severely disabled people, autism began to be viewed as a spectrum that included far less impaired children and adults. Along the way, it also became an identity, embraced by college graduates and even by some of the world’s most successful people, like Elon Musk and Bill Gates. That broadening of the diagnosis, autism experts believe, along with the increasing awareness of the disorder, is largely responsible for the steep rise in autism cases that Health Secretary Robert F. Kennedy Jr. has called “an epidemic” and has attributed to theories of causality that mainstream scientists reject, like vaccines and, more recently, Tylenol. And the diagnostic expansion has now become a flashpoint in a long-running debate over how autism should defined, one that has divided parents and activists, ignited social media battles and grown fiercer with Mr. Kennedy’s laser focus on autism. Speaking of autistic children in the spring, Mr. Kennedy said, “These are kids who will never pay taxes, they’ll never hold a job, they’ll never play baseball, they’ll never write a poem, they’ll never go out on a date.” His words drew a swift backlash from many autistic adults, who called his characterization of their lives false and dehumanizing. But Jodie’s mother, Alison Singer, said that, though she disagrees with Mr. Kennedy’s views on the causes of autism, his words about the harsh realities of living with the disorder spoke to families like her own. © 2025 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29947 - Posted: 10.01.2025

Jon Hamilton In a White House press conference Monday, President Trump and several deputies said the Food and Drug Administration would be updating drug labeling to discourage the use of acetaminophen by pregnant women, suggesting a link between the common painkiller and autism. Federal officials also said they would be changing the label for leucovorin, a form of vitamin B typically used in conjunction with cancer treatment, to enable its use as a treatment for autism. And they added that state Medicaid programs, in partnership with the federal Centers for Medicare & Medicaid Services, would cover this use. The suite of changes was announced despite a notable lack of clear scientific evidence to support these moves. The changes were presented as part of what the administration said was its commitment to identify the root causes of autism, diagnoses of which have increased in recent years. Flanked by Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid head Dr. Mehmet Oz, President Trump pinned substantial blame for rising autism rates on the common painkiller, which is also known by its brand name, Tylenol. "Taking Tylenol is not good — I'll say it: It's not good," he said, suggesting without evidence that communities without access to the medicine have "no autism," while in others, autism now affects 1 in 12 boys. (An estimated 1 in 31 children in the U.S. are diagnosed with autism.) Trump discouraged giving acetaminophen to babies, as well. (He also suggested that vaccines and their frequency may be a culprit in causing autism, an oft-repeated claim that has been debunked by decades of research.) © 2025 npr

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29941 - Posted: 09.24.2025

By Christina Caron Dr. Marty Makary, the commissioner of the Food and Drug Administration, announced on Monday that the agency would be modifying the label of a relatively obscure medicine so that “it can be available for children with autism.” He was referring to leucovorin, or folinic acid, a modified version of vitamin B9, also known as folate — which is naturally found in beans, leafy greens, eggs, beets and citrus. Folate helps the body make red blood cells and is important for cell growth. It’s especially crucial during early pregnancy to lower the risk of major birth defects in a baby’s brain or spine. Studies suggest that folate levels can affect our health in various ways, and scientists are researching what role folate plays in depression, dementia, heart disease and autism. Some people have antibodies that interfere with how folate is transported within the body, and small studies suggest that a number of people with autism — in some cases up to 75 percent — may have these antibodies. In a Federal Register notice filed on Monday, the F.D.A. said it was approving leucovorin tablets for people with “cerebral folate deficiency,” based on a review of studies from 2009 to 2024 that found that they “improve certain symptoms.” The agency, noting that more studies were needed, cited one study that compared 40 people on the medication and 40 on a placebo; those who took the medication showed “substantial improvement” of the deficiency symptoms. The medicine has been used off-label to treat people diagnosed with cerebral folate deficiency for about two decades. Symptoms of cerebral folate deficiency usually begin to show up around the age of 2 when children start to experience speech difficulties, intellectual disabilities and, in some cases, seizures. They may also have tremors and difficulty controlling their muscle movements. © 2025 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29940 - Posted: 09.24.2025

Rachel Fieldhouse Last week, a study involving more than nine million pregnancies reported that children whose mothers had gestational diabetes during pregnancy had a higher chance of developing attention deficit–hyperactivity disorder (ADHD) and autism than did children whose mothers didn’t have the condition. The study, presented at the European Association for the Study of Diabetes in Vienna, is under review at a peer-reviewed journal. It is not the first to link gestational diabetes to neurodevelopmental disorders in children, but it is one of the largest. Researchers pooled results from 48 studies across 20 countries, finding that children born to people with gestational diabetes had lower IQ scores, a 36% higher risk of ADHD and a 56% higher risk of autism spectrum disorders. Estimates suggest the prevalence of autism in the general population is one in 127 people1 and between 3-10%2 of children and teenagers have ADHD. The latest results mirror those of another meta-analysis3 published in The Lancet Diabetes & Endocrinology journal in June, which included 56 million mother–child pairs and found that all types of diabetes in pregnancy, including type 1, type 2 and gestational diabetes, increase the risk of the baby developing ADHD and autism. But none of these studies have been able to show that diabetes during pregnancy causes these conditions. “There’s no doubt that there is a signal here, but certainly further research is required,” says Alex Polyakov, an obstetrician and researcher at the University of Melbourne in Australia. Long a topic of research, the causes of autism have been thrust into the spotlight by the administration of US President Donald Trump. On Sunday, while speaking at the memorial for conservative activist Charlie Kirk, Trump said: “I think we found an answer to autism. How about that?” © 2025 Springer Nature Limited

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29939 - Posted: 09.24.2025

Helen Pearson On 16 April, Robert F. Kennedy Jr held a press conference about rising diagnoses of autism. The US Health and Human Services (HHS) secretary pointed to new data showing that autism prevalence in the United States had risen steeply from one in 150 eight-year-olds in 2000 to one in 31 in 2022. He called it an “epidemic” caused by “an environmental toxin” — and said he would soon be announcing a study to find the responsible agent. The next month, the US National Institutes of Health (NIH), part of the department that Kennedy leads, announced the Autism Data Science Initiative (ADSI). The initiative offered up to US$50 million to fund studies on the causes of autism. The winning applications are expected to be announced in September. Usually, big investments in research are welcomed by scientists — but not this time. Many were dismayed that these developments seemed to ignore decades of work on the well-documented rise in autism diagnoses and on causes of the developmental condition. Although Kennedy said that environmental factors are the main cause of autism, research has shown that genetics plays a bigger part. Population studies1 have linked a handful of environmental factors — mostly encountered during pregnancy — to increased chances of autism, but their precise role has been hard to pin down. More than anything, research has shown that the drivers of autism are fiendishly complicated. “There will never be a sound-bite answer to what causes autism,” says Helen Tager-Flusberg, a psychologist who studies neurodevelopmental conditions at Boston University, Massachusetts. The rise in prevalence, many researchers say, is predominantly caused by an increase in diagnoses rather than a true rise in the underlying symptoms and traits. “We don’t see an epidemic of autism, but we see an ‘epidemic’ of diagnoses,” says Sven Bölte, a specialist in child and adolescent psychiatric science at the Karolinska Institute in Stockholm. Researchers are concerned that Kennedy, an anti-vaccine advocate, will use the ADSI to promote the disproven idea that vaccines are linked to autism. © 2025 Springer Nature Limited

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29905 - Posted: 08.27.2025

Welcome to Entanglements. In this episode, hosts Brooke Borel and Anna Rothschild ask: Should we try to prevent autism? It’s a question that has divided the autistic community, and the answer has significant implications on how to focus scientific research and funding. Their guests this week are Jill Escher, a philanthropist, president of the National Council on Severe Autism, and parent of two young adults with severe nonverbal autism, and Eric García, the Washington bureau chief at The Independent and the author of “We’re Not Broken: Changing the Autism Conversation,” who is himself autistic. Robert F. Kennedy Jr: These are kids who will never pay taxes, they’ll never hold a job, they’ll never play baseball, they’ll never write a poem, they’ll never go out on a date. Many of them will never use a toilet unassisted. And we have to recognize we are doing this to our children. Anna Rothschild: That was Health and Human Services Secretary Robert F. Kennedy Jr., talking about autism back in April of 2025. And he promised to find some answers about the cause of the condition, which he called an epidemic. Robert F. Kennedy Jr: This is a preventable disease. We know it’s an environmental exposure. It has to be. Genes do not cause epidemics. Anna Rothschild: On that note, welcome to Entanglements, the show where we wade into the murkiest scientific controversies and search for common ground. I’m science journalist Anna Rothschild. Brooke Borel: And I’m Brooke Borel, articles editor at Undark Magazine. And that was a dramatic cold open. Anna, what’s happening here? Are you about to do an episode on whether vaccines cause autism? Anna Rothschild: No, that is not a murky controversy. That has been rigorously disproven. Brooke Borel: Yeah. Anna Rothschild: No, today we are asking the question: Should we try to prevent autism?

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29904 - Posted: 08.27.2025

By Ellen Barry Thirty-six hours after dropping his date off at her apartment, Bradley Goldman was on a video call with his dating coach, breaking down the events of the evening. Listen to this article with reporter commentary For one thing, he told the coach, he had chosen the wrong venue for someone on the autism spectrum — a bar of the Sunset Strip hipster variety, so loud and overstimulating that he could almost feel himself beginning to dissociate. Mr. Goldman, a tall, rangy 42-year-old who works as an office manager, hadn’t decided in advance of the date whether to mention that he had been diagnosed with autism, or that he was working with a coach. So he deflected, and they found themselves, briefly, in a conversational blind alley. “I struggle with how to disclose,” he said. “Do I say I am ‘neuro-spicy’? Or ‘neurodiverse’? Or do I disclose at all?” His coach, Disa Jean-Pierre, was sympathetic. “You could just wait for it to come up naturally after a few dates,” she suggested. Mr. Goldman thought this over. “I’m still figuring this out,” he said. Nevertheless, it was a solidly enjoyable date, something he credited to the coaching he had received from a team of psychologists at the Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles. He had avoided “info dumping” or making too many Jeffrey Dahmer jokes, and he had carefully observed his date’s body language to detect whether she was signaling openness to a good night kiss. (She was.) “She was like, ‘I really want you to let me know you got home,’” he said. “So, that © 2025 The New York Times Company

Related chapters from BN: Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 13: Memory and Learning
Link ID: 29826 - Posted: 06.14.2025